AU1774899A - Desaturase - Google Patents
Desaturase Download PDFInfo
- Publication number
- AU1774899A AU1774899A AU17748/99A AU1774899A AU1774899A AU 1774899 A AU1774899 A AU 1774899A AU 17748/99 A AU17748/99 A AU 17748/99A AU 1774899 A AU1774899 A AU 1774899A AU 1774899 A AU1774899 A AU 1774899A
- Authority
- AU
- Australia
- Prior art keywords
- dna sequence
- polypeptide
- fatty acid
- sequence
- organism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000194 fatty acid Substances 0.000 claims description 67
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 26
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 24
- 241000907999 Mortierella alpina Species 0.000 claims description 18
- 235000021342 arachidonic acid Nutrition 0.000 claims description 18
- 229940114079 arachidonic acid Drugs 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 13
- 239000000758 substrate Substances 0.000 claims description 12
- 108020004414 DNA Proteins 0.000 claims description 11
- 239000000523 sample Substances 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims description 10
- 238000012986 modification Methods 0.000 claims description 10
- 230000004048 modification Effects 0.000 claims description 10
- 150000003180 prostaglandins Chemical class 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims description 8
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 8
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 102000009114 Fatty acid desaturases Human genes 0.000 claims description 5
- 108010087894 Fatty acid desaturases Proteins 0.000 claims description 5
- 241000592344 Spermatophyta Species 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000002068 genetic effect Effects 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 235000007689 Borago officinalis Nutrition 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 244000061176 Nicotiana tabacum Species 0.000 claims description 4
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 3
- 240000004355 Borago officinalis Species 0.000 claims description 3
- 241000244203 Caenorhabditis elegans Species 0.000 claims description 3
- 241000195493 Cryptophyta Species 0.000 claims description 3
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 241000233788 Arecaceae Species 0.000 claims description 2
- 244000056139 Brassica cretica Species 0.000 claims description 2
- 235000003351 Brassica cretica Nutrition 0.000 claims description 2
- 240000002791 Brassica napus Species 0.000 claims description 2
- 235000006008 Brassica napus var napus Nutrition 0.000 claims description 2
- 235000003343 Brassica rupestris Nutrition 0.000 claims description 2
- 244000020518 Carthamus tinctorius Species 0.000 claims description 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 claims description 2
- 235000013162 Cocos nucifera Nutrition 0.000 claims description 2
- 229920000742 Cotton Polymers 0.000 claims description 2
- 235000001950 Elaeis guineensis Nutrition 0.000 claims description 2
- 244000127993 Elaeis melanococca Species 0.000 claims description 2
- 244000068988 Glycine max Species 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- 244000299507 Gossypium hirsutum Species 0.000 claims description 2
- 244000020551 Helianthus annuus Species 0.000 claims description 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 2
- 240000006240 Linum usitatissimum Species 0.000 claims description 2
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 2
- 241000219925 Oenothera Species 0.000 claims description 2
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 2
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 235000004443 Ricinus communis Nutrition 0.000 claims description 2
- 244000000231 Sesamum indicum Species 0.000 claims description 2
- 235000003434 Sesamum indicum Nutrition 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 claims description 2
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000004426 flaxseed Nutrition 0.000 claims description 2
- 235000021374 legumes Nutrition 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 235000010460 mustard Nutrition 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 230000001850 reproductive effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 11
- 239000002299 complementary DNA Substances 0.000 description 11
- 150000004665 fatty acids Chemical class 0.000 description 11
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 10
- 238000004817 gas chromatography Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 238000013519 translation Methods 0.000 description 8
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 229930182830 galactose Natural products 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000005253 yeast cell Anatomy 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 241000306281 Mucor ambiguus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 229940040452 linolenate Drugs 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 240000002900 Arthrospira platensis Species 0.000 description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010007167 Cytochromes b5 Proteins 0.000 description 2
- 102000007605 Cytochromes b5 Human genes 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 208000033962 Fontaine progeroid syndrome Diseases 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000010230 functional analysis Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- LGHXTTIAZFVCCU-SSVNFBSYSA-N (2E,4E,6E,8E)-octadeca-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O LGHXTTIAZFVCCU-SSVNFBSYSA-N 0.000 description 1
- ZEBIJPXNSBSHGD-ZKWNWVNESA-N (5z,8z,11z,14z)-2-methylicosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCC(C)C(O)=O ZEBIJPXNSBSHGD-ZKWNWVNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 241001072256 Boraginaceae Species 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241000192584 Synechocystis Species 0.000 description 1
- 241000192581 Synechocystis sp. Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 229940066279 eicosapentaenoate Drugs 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- ZGNITFSDLCMLGI-UHFFFAOYSA-N flubendiamide Chemical compound CC1=CC(C(F)(C(F)(F)F)C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(I)=C1C(=O)NC(C)(C)CS(C)(=O)=O ZGNITFSDLCMLGI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 239000008161 low-grade oil Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006259 progesterone secretion Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 108010009106 sphingolipid desaturase Proteins 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0083—Miscellaneous (1.14.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
- C12N15/8247—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine involving modified lipid metabolism, e.g. seed oil composition
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C12P7/6445—Glycerides
- C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Fats And Perfumes (AREA)
Description
WO 99/33958 PCT/GB98/03895 1 DESATURASE This invention relates to DNA sequences encoding A5-fatty acid desaturases, the encoded A5-fatty acid desaturases, and applications for the A5-fatty acid desaturases. Polyunsaturated fatty acids are important neutraceutically due to their specific health promoting activities, and biomedically in respect of their potential pharmaceutical applications in the treatment of specific disease conditions. Polyunsaturated fatty acids are the precursors for two major classes of metabolites: prostanoids (which include prostaglandins and thromboxanes) and leukotrienes. A5-fatty acid desaturase catalyses the conversion of dihomogamma linolenic acid (DHL) to arachidonic (AA) acid, and eicosatetraenoate (ETA) to ecosapentaenoate (EPA), by the introduction of double bonds at the A5 carbon of the respective substrates, and exists as an endoplasmic reticulum membrane-bound protein in its native state. Arachidonic acid has a 20 carbon chain with 4 double bonds and is of great importance in human metabolism since it is a precursor for the synthesis of prostaglandins - 20-carbon chain fatty acids that contain a 5 carbon ring. Prostaglandins are modulators of hormone action and the potential effects of prostaglandins include the stimulation of inflammation, the regulation of blood flow to particular organs, the control of ion transport across some membranes, and the modulation of synaptic transmission. Prostaglandins are also potentially useful as contraceptives due to their ability to suppress progesterone secretion. Therefore, the ability to modulate prostaglandin synthesis by controlled levels of WO 99/33958 PCT/GB98/03895 2 expression of polyunsaturated fatty acid precursor synthesis is very important both medically and commercially. The increased importance of polyunsaturated fatty acids in the food and pharmaceutical industries has led to an increased demand which has exceeded current production levels and supplementary sources of high quality, low cost polyunsaturated fatty acids are required. Current commercial sources of polyunsaturated fatty acids include selected seed plants, marine fish and selected mammals, and traditional processing techniques for extracting the polyunsaturated fatty acids from these sources include solvent extraction, winterization, urea-adduct formation and distillation. However, present sources have the disadvantages of seasonal and climatic variations in both production levels and quality, a lack of availability of plant and fish sources, and the high costs of refining low-grade oils. High costs coupled with insufficient production levels have retarded the development of commercially exploitable applications of polyunsaturated fatty acids. Much effort has gone into developing alternative sources of polyunsaturated fatty acids, and studies have been carried out to characterise the constituent genes and encoded proteins of their biosynthesis. The engineering of polyunsaturated fatty acid biosynthesis into oilseeds for example has many advantages for the production of large scale quantities of, for example, y-linolenate (GLA), dihomo-y(-linolenate (DHGLA), arachidonic acid (AA), eicosapentaenoate (EPA) and docosahezaenoate (DHA). The practicality of this has been illustrated by the expression of a Borage A6 desaturase gene in tobacco resulting in WO 99/33958 PCT/GB98/03895 3 the production of GLA and the octadecatetraenoic acid, 18:4 (Soyanova et al (1997), PNAS 94, 9411-9414). As more of the biosynthetic genes for polyunsaturated fatty acid synthesis become available, this opens up the possibility of producing at least GLA, AA, EPA and DHA in oil seeds, as well as controlling the type of lipid assembled. Benefits which would be obtained from such crops include a cheap and sustainable supply of desirable polyunsaturated fatty acids on a large scale, tailored polyunsaturated fatty acids profiles to meet specific nutritional requirements, and in the fine chemical industry, the production of unusual fatty acids with prescribed levels and locations of unsaturation. A further approach to the production of polyunsaturated fatty acids is to utilise the biosynthetic capacity of lower organisms e.g. algae, bacteria, fungi (including phycomycetes) which can synthesise the entire range of polyunsaturated fatty acids and can be grown on an industrial scale. Genetic transformation of these organisms will enable the development of overproducing strains and the manipulation of the polyunsaturated profile by pathway engineering. Fungal A5 and A6 fatty acid desaturases have been cloned, and their sequences disclosed in W098/46763, W098/46764 and W098/46765. Polyunsaturated fatty acid metabolism is of greatest importance in human metabolism. These acids, via the eicosanoids, are fundamental to the proper maintenance of homeostasis and are linked to serious physiological and pathophysiological syndromes.
WO 99/33958 PCT/GB98/03895 4 The inventors have surprisingly isolated and characterised a DNA sequence from the soil-borne filamentous fungus of the zygomycete class Mortierella alpina encoding a functional A5-fatty acid desaturase. In addition, the inventors have surprisingly isolated and characterised a DNA sequence from the nematode worm, Caenorhabditis elegans encoding a functional A5-fatty acid desaturase. This DNA sequence, encoding a functional A5-fatty acid desaturase is thought likely to be more closely related to the human A5-fatty acid desaturase than any of the A5-fatty acid desaturase gene sequences isolated so far. As well as the potential human benefits from the polypeptide encoded by the DNA sequences of this invention, the DNA sequences of this invention may enable the cloning of the equivalent human gene and thereby facilitate overproduction of the human DNA sequence and allow its biomedical exploitation in the treatment of certain human diseases. Plant and fungal desaturases are mainly integral membrane polypeptides which makes them difficult to purify and subsequently characterise by conventional methods. Hence, molecular techniques including the use of mutants and transgenic plants have been adopted in order to better study lipid metabolism. A first aspect of the invention provides an isolated animal A5-fatty acid desaturase and functional portions thereof. A second aspect of the invention provides an isolated C. elegans A5-fatty acid desaturase.
WO 99/33958 PCT/GB98/03895 5 A third aspect of the invention provides a DNA sequence according to a first or second aspect of the invention comprises at least a portion of the sequence shown in SEQ.2 and equivalents to that sequence, or to portions of that sequence, which encode a functional A5-fatty acid desaturase by virtue of the degeneracy of the genetic code. Preferably, the DNA sequence is derived from a Caenorhabditis elegans DNA sequence. Preferably, the gene encoding the A5-fatty acid desaturase encoded by the cloned gene is 1341 bp long. The protein is 447 amino acids long with an estimated molecular weight of 57 kDa. Alternatively, the DNA sequence encodes a functional A5-fatty acid desaturase and comprises at least a portion of the sequence shown in SEQ.1 and equivalents to that sequence, or to portions of that sequence, which encode a functional A5-fatty acid desaturase by virtue of the degeneracy of the genetic code. Preferably, the DNA sequence is derived from a Mortierella alpina DNA sequence. Preferably, the gene encoding the A5-fatty acid desaturase encoded by the cloned gene is 1338 bp long. The protein is 446 amino acids long with an estimated molecular weight of 57 kDa. Preferably, a DNA sequence according to a third aspect of the invention is functional in a mammal. Preferably, the DNA sequence is expressed in a mammal. Preferably. the DNA sequence is expressed in a human. Preferably, the DNA sequence is obtained by modification of a functional natural gene encoding a A-5 fatty acid desaturase. Preferably, the modification includes modification by chemical, physical, or biological means without removing a catalytic activity of the enzyme which it encodes. Preferably, the modification improves a catalytic activity of the enzyme which it encodes.
WO 99/33958 PCT/GB98/03895 6 Preferably, the biological modification includes recombinant DNA methods and forced evolution techniques. Preferably, the forced evolution technique is DNA shuffling. A fourth aspect of the invention provides a polypeptide encoded by a DNA sequence according to a third aspect of the invention. Preferably, at least a portion of the polypeptide has the sequence shown in SEQ.3 or functional equivalents to that sequence or portions of that sequence. Alternatively, at least a portion of the polypeptide has the sequence shown in SEQ.4 or functional equivalents to that sequence or portions of that sequence. Preferably, the polypeptide catalyses the conversion of dihomogamma linolenic acid to arachidonic acid. Preferably, the polypeptide has been modified without removing the catalytic activity of the encoded polypeptide. Preferably, the polypeptide has been modified in such a way as to introduce a specific level of saturation of a substrate at a specific location within the molecular structure of the substrate. A fifth aspect of the invention provides a vector containing a DNA sequence of any portion of a DNA sequence according to a third aspect of the invention.. A sixth aspect of the invention provides a method of producing polyunsaturated fatty acids comprising contacting a substrate with a A5-fatty acid desaturase according to a first or second aspect of the invention, or a polypeptide according to a fourth aspect of the invention. A seventh aspect of the invention provides a method of converting dihomogamma linoleic acid to arachidonic acid wherein the conversion is catalysed by a A5-fatty acid desaturase according to a first or second aspect of the invention, or a polypeptide according to a fourth aspect of the invention.
WO 99/33958 PCT/GB98/03895 7 An eighth aspect of the invention provides an organism engineered to produce high levels of a polypeptide according to a fourth aspect of the invention. A ninth aspect of the invention provides an organism engineered to produce high levels of a product of a reaction catalysed by a A5-fatty acid desaturase according to a first or second aspect of the invention, or by a polypeptide according to a fourth aspect of the invention. Preferably, the organism has been engineered to carry out the method according to a sixth or seventh aspect of the invention. Preferably, the organism is a microorganism. Preferably, the microorganism is selected from algae, bacteria and fungi. Preferably, the fungi includes phycomycetes. Alternatively, the microorganism is a yeast. Alternatively, the organism is a plant. Preferably, the plant is selected from oil seed plants. Preferably, the oil seed plants are selected from oil seed rape, sunflower, cereals including maize, tobacco, legumes including peanut and soybean, safflower, oil palm, coconut and other palms, cotton, sesame, mustard, linseed, castor, borage and evening primrose. A tenth aspect of the invention provides a seed or other reproductive material derived from an organism according to a ninth aspect of the invention. Preferably, the organism is a mammal. An eleventh aspect of the invention provides an isolated multienzyme pathway wherein the pathway includes a A5-fatty acid desaturase according to a first or second aspect of the invention. A twelfth aspect of the invention provides a compound produced by a conversion of a substrate, wherein said conversion is catalysed by a A5-fatty acid desaturase according to a first or second aspect of the invention.
WO 99/33958 PCT/GB98/03895 8 A thirteenth aspect of the invention provides an intermediate compound produced by the reaction catalysed by a A5-fatty acid desaturase according to a first or second aspect of the invention. A fourteenth aspect of the invention provides a foodstuff or dietary supplement containing a polyunsaturated fatty acid produced by a method according to a sixth aspect of the invention. A fifteenth aspect of the invention provides a pharmaceutical preparation containing a polyunsaturated fatty acid produced by a method according to a sixth aspect of the invention. A sixteenth aspect of the invention provides prostaglandins synthesised by a biosynthetic pathway including a catalytic activity of a A5-fatty acid desaturase according to a first or second aspect of the invention. A seventeenth aspect of the invention provides a method for the modulation of prostaglandins synthesis by the control of the levels of expression of a DNA sequence according to a third aspect of the invention. An eighteenth aspect of the invention provides a probe comprising all or part of a DNA sequence according to a third aspect of the invention,or an equivalent RNA sequence. A nineteenth aspect of the invention provides a probe comprising all or part of a A5-fatty acid desaturase polypeptide according to a fourth aspect of the invention. A twentieth aspect of the invention provides a method of isolating A5-fatty acid desaturases using a probe according to a nineteenth aspect of the invention. It is possible that the gene of the invention may be transformed into human cells and exploited in gene therapy techniques at a suitable level in vivo to provide a constant supply of enzyme converting fatty acids to polyunsaturated fatty acids within the patient's body. This could be an effective preventative treatment for example, in patients suffering high WO 99/33958 PCT/GB98/03895 9 levels of cholesterol or other medical conditions where administration of polyunsaturated fatty acids may have beneficial disease-preventative effects. In addition, either whole or part of the DNA sequences of the invention, or whole or part of the polypeptide sequences of the invention could be used as search probes for research or diagnostic purposes. The invention will now be described by way of example only, with reference to the accompanying drawings, SEQ. 1 to SEQ.4, and Figs. 1 to 4, in which: SEQ. 1 is a cDNA sequence encoding A5-fatty acid desaturase from Mortierella alpina and; SEQ.2 is a cDNA sequence encoding A5-fatty acid desaturase from C. elegans; and SEQ.3 is the peptide sequence obtained by translating the gene sequence of SEQ. 1; and SEQ.4 is the peptide sequence obtained by translating the gene sequence of SEQ2; and Fig. 1 is a line-up of the gene encoding Mortierella alpina A5-fatty acid desaturase with various A6 desaturases and a A12 desaturase; and Fig. 2 is a line-up of the gene encoding A5-fatty acid desaturase with the C. elegans A6 desaturase and the fungal A5 desaturase from M. alpina; and Fig. 3 is a gas chromatography trace of the fatty acid methyl esters of induced yeast cell transformants transformed with the Mortierella alpina A5-fatty acid desaturase gene and uninduced yeast cell transformants; and WO 99/33958 PCT/GB98/03895 10 Fig. 4 is a gas chromatography trace of the fatty acid methyl esters of induced yeast cell transformants transformed with the C. elegans A5-fatty acid desaturase gene and uninduced yeast cell transformants. Cloning and sequencing of the A5-fatty acid desaturase gene from Mortierella alpina The DNA sequences of the invention encode A5-fatty acid desaturases and were cloned using PCR technology in combination with cDNA library templates and specifically designed primers. The function of the DNA sequences, namely the conversion of dihanogamma linolenic acid (DHL) to arachidonic acid (AA), and eicostatetraenoate (ETA) to ecosapentaenoate (EPA), were verified by expressing the corresponding cDNAs in yeast. The A5-fatty acid desaturase gene from Mortierella alpina was cloned by Polymerase Chain Reaction (PCR) techniques using cDNA from Mortierella alpina as the template and specifically designed degenerate oligonucleotide primers (DP) as shown below, based on the first and third histidine bases of plant A12 and A15 desaturases previously identified by Shanklin (Shanklin, J, Whittle, E J & Fox, BG. Biochemistry. 33, 12787-12794 (1994)). Degenerate oligonucleotide primers (DP) 5'-GCGAATTA(A/T)TIGGICA(T/C)GA(T/C)TG(T/C)GICA-3' 5'-GCGAATTCATIT(G/T)IGG(A/G)AAIA(G/A)(A/G)TG(A/G)TG-3' where I represents inosine, and the Eco RI sites are underlined.
WO 99/33958 PCT/GB98/03895 11 The PCR amplifications were run entirely conventionally on a thermal cycler made by using a program of 2 minutes at 94 'C then 45 seconds at 94 'C, 1 minute at 55 0 C and 1 minute at 72 "C for 32 cycles followed by extension at 72 'C for a further 10 minutes. PCR amplification products were separated on 1 % agarose gels. The range of PCR products amplified from the Mortierella alpina cDNA template included a 660 bp product which was gel purified, cloned into pGEM-T (Promega RTM) and transformed into the Escherichia coli expression host, DH5at. Primers (P) were designed against the 660 bp product sequence and fragment amplification carried out by PCR using the cloned 660 bp fragment as a template, and sequence-specific primers (P) based on the 660 bp product sequence. Delta B for 5'-GATGCGTCTCACTTTTCA-3' Delta B rev. 5'-GTGGTGCACAGCCTGGTAGTT-3' The products of this PCR amplification were gel purified and used as probes to screen a Mortierella alpina cDNA library. The fragment probe hybridised to 25 out of the 3.5 x 10 phage clones screened and one clone was shown, by restriction analysis, to have the expected size of 1.5 kb. This clone, designated Li 1, was selected for further analysis.
WO 99/33958 PCT/GB98/03895 12 Sequence analysis of L 11 revealed an open reading frame of 1,338 bp in length encoding a polypeptide of 446 amino acids. When analyzed on the protein and genomic databases using the GCG 8 Program (Devereux J. et al. Nucleic Acids. Res.. 12, 387-395 (1984)), L 11 showed a low level 20% identity to the A6 desaturase gene from Synechocystis sp. PCC6803 (Fig. 1). In Fig. 1, the sequences in the line-up have the following Accession numbers: S54259 A12 Spirulina Accession number: X86736 S54809 A6 Spirulina Accession number: X87094 S68358 Putative Sphingolipid desaturase Accession number: X87143 S35157 A6 Synechocystis Accession number: L 11421 PBOR6 A6 Borage Accession number U79010 FU2 A5 desaturase Accession number AF054824 In addition, although all three histidine boxes characteristic of desaturase enzymes are present in the translated sequence, the third histidine box located at position 1159 bp in the sequence contains the variant QXXHH. The translated sequence also contains a cytochrome b 5 -like heme-binding domain at the N-terminus which includes the EHPGG motif whereas previously, this feature has only been observed at the C-terminus of other fungal desaturases. Southern blotting of genomic DNA Sequence specific primers (P) designed against the Li I sequence between histidine boxes 1 and 3 of Li 1, were used in a PCR reaction to amplify a 660 bp region of the L 11 sequence.
WO 99/33958 PCT/GB98/03895 13 The 660 bp PCR product was gel purified and Southern blots of restricted Mortierella alpina and Mucor circinelloides genomic DNA carried out using the 660 bp fragment as a probe. The results suggest that the gene encoding the A5-fatty acid desaturase of the invention is present in single copy in Mortierella alpina and appears to be absent from Mucor circinelloides. In addition, there is no detectable A5-fatty acid desaturase activity in Mucor circinelloides. Expression of the cloned Mortierella alpina gene encoding A5-fatty acid desaturase In order to confirm that the L 11 sequence encoded a A5-fatty acid desaturase enzyme, the cDNA was subcloned into the yeast expression vector, pYES2, supplied by Invitrogen TM under the control of the GAL4 polymerase promoter to yield plasmid pYES2/L1 1. The expression of L 11 was checked by in vitro transcription-translation of pYES2/L 11 using the PromegaTM coupled Transcription and Translation system. "S methionine-labelled translation products were generated which were run on SDS PAGE and visualised by exposure to autoradiograph film. The estimated molecular weight of the product was 55-60 kD and a control plasmid, pYES2 with no insert, failed to yield any labelled translation product. Construct, pYES2/L1 1, was transformed into yeast Saccharomyces cerevisiae and grown on uracil-deficient YCA medium. Transformants were selected by virtue of the presence of the URA3 selectable marker carried by pYES2/L11 and expression of L 11 was induced by the addition of galactose to a final concentration of 1% mM. The cultures were grown overnight in the presence of 0.5 mM dihomo gamma linolenate, detergent (1% tergitol NP-40) and 2% raffinose. Aliquots were harvested at t=0, t=4 hours, and t= 16 hours.
WO 99/33958 PCT/GB98/03895 14 Yeast total fatty acids were analysed by GC of methyl esters. The lipids from the induced and uninduced control samples were transmethylated with IM HCL in methanol at 80'C for 1 hr. Fatty acid methyl esters (FAMES) were extracted in hexane. GC analysis of FAMES was conducted using a Hewlett Packard 58804 Series Gas Chromatograph equipped with a 25M x 0.32 mm RSL-500 BP bonded capillary column and a flame ionization detector. When methyl esters of the total fatty acids isolated from yeast carrying the plasmid pYes2/L 11 and grown in the presence of galactose and dihomo gamma linolenic acid were analysed by GC an additional peak was observed (see Fig. 3). This extra peak had the same retention time as the authentic arachidonic acid standard (Sigma) indicating that the transgenic yeast were capable of desaturating Dihomo gamma linolenic acid at the A5 position. No such peaks were observed in any of the control samples (transformation with pYes2) Fig. 3. The identity of the additional peak was confirmed by GCMS (Kratos MS80RFA operating at an ionization voltage of 70 eV with a scan range of 500-40 daltons) which positively identified this compound as arachidonic acid. This demonstrates that the DNA sequence from Mortierella alpina encodes a functional polypeptide involved in the synthesis of arachidonic acid in the presence of galactose and dihomo gamma linolenate. Cloning and sequencing of the C. elegans A5-fatty acid desaturase gene Previously, the inventors identified fungal A5 and A6-fatty acid desaturases from both plant and animal species which were distinct from previously identified microsomal WO 99/33958 PCT/GB98/03895 15 desaturases. This difference was due to the presence of an N-terminal extension which showed homology to the electron donor protein cytochrome b 5 . During the characterisation of the fungal (Mortierella alpina) A5-fatty acid desaturase and the C.elegans A6-fatty acid desaturase (present on cosmid W08D2 (Accession No. Z70271)), the inventors identified a related sequence on cosmid T13F2.1 (Accession No. Z81122) also containing C.elegans DNA likely to encode a fatty acid desaturase. Analysis of the sequences (using Genefinder program (Wilson, R. et al (1994) Nature, 368, 32-38)) revealed that cosmids W08D2 and T13F2 contained overlapping regions. In addition, it was found that cosmid T13F2 contained an open reading frame (ORF), designated T13F2.1, which contained an N-terminal cytochrome bs domain (defined by the diagnostic His-Pro-Gly-Gly motif), as well as three 'histidine boxes' characteristic of all microsomal desaturases. Further, this putative desaturase contained a variant third histidine box, with a H-+Q substitution for the first histidine in the His-X-X-His-His motif. This glutamate substitution is present in both plant and animal A6-fatty acid desaturases and in the fungal A5-fatty acid desaturase from M.alpina. The overlap between cosmids T13F2 and W08D2 allowed the determination of the proximity of the putative desaturase ORF, Ti 3F2. 1, to the A6-fatty acid desaturase, revealing that the two sequences were arranged in tandem on chromosome IV, separated by 990 bases from the predicted stop codon of T13F2.1 to the initiating methionine triplet of the A6-fatty acid desaturase.
WO 99/33958 PCT/GB98/03895 16 Since sequence analysis predicted that the T13F2.1 ORF was interspersed with a number of introns, heterologous functional expression of genomic DNA was unfeasible. Therefore, the polymerase chain reaction (PCR) was used to amplify a partial cDNA clone corresponding to a large predicted exon at the 5'end of the T13F2.1 ORF using the following primers, CEFOR AND CEREV: CEFOR: 5' - ATGGTATTACGAGAGCAAGA-3' CEREV: 5'-TCTGGGATCTCTGGTTCTTG-3' After initial denaturation at 94 'C for 2 minutes, amplification was performed in 32 cycles of: 45 seconds at 94 'C, 1 minute at 55 'C, and 1 minute at 72 'C followed by a final extension at 72 'C for a further 10 minutes. A DNA fragment of the correct predicted size was amplified (as visualised on a 1% agarose gel), the gel band was cut out, the DNA purified and ligated directly into pGEM-T (Promega), and the resulting plasmid transformed into E.coli DH5X cells. Plasmid DNA was purified for sequencing using the Qiagen QlAprep miniprep kit, and the nucleotide sequence of the insert determined by automated sequencing using an ABI-377 DNA sequencer.
WO 99/33958 PCT/GB98/03895 17 In order to isolate the complete coding region corresponding to ORF T13F2.1, this isolated 233 bp PCR-amplified fragment was used to screen a mixed stage C.elegans cDNA library that had been constructed in XZapII by Prof Yuji Kohara - Mishima, Japan. The screening was carried out using standard techniques (Sambrook et al (1989) Molecular Cloning. A Laboratory Manual) using the cloned PCR product as a probe. The DNA fragments were labelled with a [ 32 P] d CTP using the Ready to Go DNA-Labelling reaction mix (Pharmacia). Of 1.4 x 10' pfu screened for hybridization to the 233bp fragment, 5 plaques gave positive signals and were cored out of the agar plates and eluted into SM buffer . The resultant phage suspensions were screened for the presence of T13F2.1 by PCR amplification using CEFOR and CEREV. One clone, designated L4, was purified by 2 additional rounds of plating and hybridisation screening at 65'C using the 233bp fragment isolated by PCR. Plasmid L4 was released from X clone L4 by excision and the cDNA insert sequenced on both strands using a Perkin Elmer AB 1-377 DNA sequencer. The resulting DNA sequence is shown in SEQ.2, and the predicted amino acid sequence is shown in SEQ.4. Functional analysis of L4 in yeast The complete coding region (coding for 447 amino acids) of LA was amplified by PCR using the primers YCEDFor and TCEDRev shown below, which also introduced flanking HindIII and BamHI restriction sites: YCEDFor: 5'-GCGAAGCTTAAAATGGTATTACGAGAGCAAGAGC-3' WO 99/33958 PCT/GB98/03895 18 (annealing to the initiating methionine is indicated by the bold type face and the Hind III restriction site is underlined) YCEDRev: 5'-GCGGGATCCAATCTAGGCAATCTTTTTAGTCAA-3' (annealing to the complement of the stop codon, indicated by the bold type face and the BamH I restriction is underlined) The amplified PCR product containing the complete coding region of L4 was ligated into the yeast expression vector, pYES2 (Invitrogen), downstream of the GALl promoter using HindIII and BamIl restriction sites (enzymes supplied by Boehringer Mannheim). The resulting construct, designated pYES2/L4, was transformed into E.coli, and the fidelity of the PCR-generated insert in plasmid pYES2/L4 was confirmed in vitro by coupled transcription/translation using the TNT system (Promega). The resulting translation products were labelled with 3 sS methionine, separated by SDS-PAGE and visualised by autoradiography. The translation product obtained from pYES2/L4 had a molecular weight of approximately Mr57,000, whereas the control vector, pYES2 with no insert, did not yield a translation product. For functional analysis of the L4 coding region the recombinant plasmid was transformed into S. cerevisiae DBY746 by the lithium acetate method (Elble R. (1992) Bio Techniques 13 18-20). Cells were cultured overnight in a medium containing raffinose as a carbon WO 99/33958 PCT/GB98/03895 19 source, and supplemented by the addition of either linoleic acid (18:2 A 9 ,1 2 ) or di-homo-y-linolenic acid (C20:3 A""' 1 4 ) in the presence of 1% tergitol (as described by Napier et al (1998) Biochem. J. 330 611-614). These fatty acids are not present in S. cerevisiae but serve as the specific substrates for either the A 6 or A-desaturase, respectively. Expression of the L4 coding region from the GAL] promoter of the vector was induced by the addition of galactose to 1%. Growth of the cultures was continued for 16 hours before removal of aliquots for the analysis of fatty acids by GC Total fatty acids extracted from yeast cultures were analysed by gas chromatography (GC) of methyl esters. Lipids were transmethylated with IM HCl in methanol at 80'C for 1 hr, then fatty acid methyl esters (FAMEs) were extracted in hexane. GC analysis of FAMEs were conducted using a Hewlett Packard 5880A Series Gas chromatograph equipped with a 25 M x 0.32 mm RSL-500 BP bonded capillary column and a flame ionization detector. Fatty acids were identified by comparison with retention times of FAME standards (Sigma). Relative percentages of the fatty acids were estimated from peak areas. Arachidonic acid was identified by GC-MS using a Krats MS80RFA operating at an ionization voltage of 70 eV, with a scan range of 500-40 daltons. Figure 4 shows the result of GC analysis of the fatty acid methyl esters of transformed yeast strains. An additional peak is apparent in the trace obtained from induced pYES2/L4 grown in the presence of di-homo-y-linolenic acid compared to an empty-vector control. This peak was also absent from uninduced cultures grown on di-homo-y-linolenic acid and it is also important to note that pYES2/L4 grown in the presence of linoleic acid failed to accumulate any novel peaks indicating that this fatty acid is not a substrate for the enzyme encoded by the C. elgans cDNA. The retention time of the additional peak is identical to that of the authentic methyl-arachidonic acid standard. The fatty acid produced from di-homo-y-linolenic acid was further characterised by GCMS WO 99/33958 PCT/GB98/03895 20 (Gas Chromatography Mass Spectrometry) and identified as arachidonic acid. The results show, therefore, that yeast cells transformed with the plasmid pYES2/L4 had acquired functional A-desaturase activity and were now capable of synthesising arachidonic acid from the substrate di-homo-y-linolenic acid. The A-desaturase in the transformed yeast appeared to be an efficient catalyst. This demonstrates that the DNA sequence from C. elegans encodes a functional polypeptide involved in the synthesis of arachidonic acid in the presence of galactose and di-homo-y-linolenate.
WO 99/33958 PCT/GB98/03895 21 SEc 2. 1 ATGGTATTAC GAGAGCAAGA GCATGAGCCA TTCTTCATTA AAATTGATGG 51 AAAATGGTGT CAAATTGACG ATGCTGTCCT GAGATCACAT CCAGGTGGTA 101 GTGCAATTAC TACCTATAAA AATATGGATG CCACTACCGT ATTCCACACA 151 TTCCATACTG GTTCTAAAGA AGCGTATCAA TGGCTGACAG AATTGAAAAA 201 AGAGTGCCCT ACACAAGAALC CAGAGATCCC AGATATTAAG GATGACCCAA 251 TCAAAGGAAT TGATGATGTG AACATGGGAA CTTTCAATAT TTCTGAGAAA 301 CGATCTGCCC AAATAAATAA AAGTTTCACT GATCTACGTA TGCGAGTTCG 351 TGCAGAAGGA CTTATGGATG GATCTCCTTT GTTCTACATT AGAAAAATTC 401 TTGAAACAAT CTTCACAATT CTTTTTGCAT TCTACCTTCA ATACCACACA 451 TATTATCTTC CATCAGCTAT TCTLATGGGA GTTGCGTGGC AACAATTGGG 501 ATGGTTAATC CATGAATTCG CACATCATCA GTTGTTCAAA AACAGATACT 551 ACAATGATTT GGCCAGCTAT TTCGTTGGAA ACTTTTTACA AGGATTCTCA 601 TCTGGTGGTT GGAAAGAGCA GCACAATGTG CATCACGCAG CCACAAATGT 651 TGTTGGACGA GACGGAGATC TTGATTTAGT CCCATTCTAT GCTACAG7GG 701 CAGAACATCT CAACAATTAT TCTCAGGATT CATGGGTTAT GACTCTATTC 751 AGATGGCAAC ATGTTCATTG GACATTCATG TTACCATTCC TCCGTCTCTC 801 GTGGCTTCTT CAGTCAATCA TTTTTGTTAG TCAGATGCCA ACTCATTATT 851 ATGACTATTA CAGAAATACT GCGATTTATG AACAGGTTGG TCTCTCTTTG 901 CACTGGGCTT GGTCATTGGG TCAATTGTAT TTCCTACCCG ATTGGTCAAC 951 TAGAATAATG TTCTTCCTTG TTTCTCLTCT TGTTGGAGGT TTCCTGCTCT 1001 CTCATGTAGT TACTTTCAAT CATTATTCAG TGGAGAAGTT TGCATTGAGC 1051 TCGAACATCA TGTCAAATTA CGCTTGTCTT CAAATCATGA CCACAAGAAA 1101 TATGAGACCT GGAAGATTCA TTGACTGGCT TTGGGGAGGT CTTAACTATC 1151 AGATTGAGCA CCATCTTTTC CCAACGATGC CACGACACAA CTTGAACACT 1201 GTTATGCCAC TTGTTAAGGA GTTTGCAGCA GCAAATGGTT TACCATACAT 1251. GGTCGACGAT TATTTCACAG GATTCTGGCT TGAAATTGAG CAATTCCGAA 1301 ATATTGCAAA TGTTGCTGCT AAATTGACTA AAAAGATTGC CTAG SUBSTITUTE SHEET (RULE 26) WO 99/33958 PCT/GB98/03895 22 1 MGTDQGKTFT WEELAAHNTK GDLFLAIRGR VYDVTKFLSR HPGGVDTLLL 51 GAGRDVTPVF ZMYHAFGAAD AIMKKYYVGT LVSNELPVFP EPTVFHKTIK 101 TRVEGYFTDR DIDPKNRPEI WGRYALIFGS LIASYYAQLF VPFVVERTWL 151 QVVFAIIMGF ACAQVGLNPL HDASHFSVTH NPTVWKILGA THDFFNGASY 201 LVWMYQHMLG HHPYTNIAGA DPDVSTFEPD VRRIKPNQKW FVNHINQDMF 251 VPFLYGLLAF KVRIQDINIL YFVKTNDAIR VNPISTWHTV MFWGGKAFFV 301 WYRLIVPLQY LPLGKVLLLF TVADMVSSYW LALTFOANHV VEEVQWPLPD 351 ENGIIQKDWA AMQVETTQDY AHDSHLWTSI TGSLNYQAVH HLFPNVSQHH 401 YPDILAIIKN TCSEYKVPYL VKDTFWQAFA SHLEHLRVLG LRPKEE* WO 99/33958 PCT/GB98/03895 23 SEq NThe predicted amino acid sequence of L4 the gene which encodes a A 5 fatty acid desaturase from C. elegans. 1 MVLREQEHEP FFIKIDGKWC QIDDAVLRSH PGGSAITTYK NMDATTVFHT 51 FHTGSKEAYQ WLTELKKECP TQEPEIPDIK DDPIKGIDDV NMGTFNISEK 101 RSAQINKSFT DLRMRVRAEG LMDGSPLFYI RKILETIFTI LFAFYLQYHT 151 YYLPSAILMG VAWQQLGWLI HEFAHHQLFK NRYYNDLASY FVGNFLQGFS 201 SGGWKEQHNV HHAATNVVGR DGDLDLVPFY ATVAEHLNNY SQDSWVMTLF 251 RWQHVHWTFM LPFLRLSWLL QSIIFVSQMP THYYDYYRNT AIYEQVGLSL 301 HWAWSLGQLY FLPDWSTRIM FFLVSHLVGG FLLSHVVTFN HYSVEKFALS 351 SNIMSNYACL QIMTTRNMRP GRFIDWLWGG LNYQIEHHLF PTMPRHNLNT 401 VMPLVKEFAA ANGLPYMVDD YFTGFWLEIE QFRNIANVAA KLTKKIA* SUBSTITUTE SHEET (RULE 26)
Claims (46)
1. An isolated animal A5-fatty acid desaturase and functional portions thereof.
2. Isolated C. elegans A5-fatty acid desaturase.
3. A DNA sequence encoding a A5-fatty acid desaturase according to claim 1 or claim 2.
4. A DNA sequence according to claim 3 and comprising at least a portion of the sequence shown in SEQ.2 and equivalents to that sequence, or to portions of that sequence, which encode a functional A5-fatty acid desaturase by virtue of the degeneracy of the genetic code.
5. A DNA sequence according to claim 4 derived from a Caenorhabditis elegans DNA sequence.
6. A DNA sequence according to claim 3 encoding a functional A5-fatty acid desaturase and comprising at least a portion of the sequence shown in SEQ. 1 and equivalents to that sequence, or to portions of that sequence, which encode a functional A5-fatty acid desaturase by virtue of the degeneracy of the genetic code.
7. A DNA sequence according to claim 6 derived from a Mortierella alpina DNA sequence.
8. A DNA sequence according to any one of claims 3 to 7 wherein the DNA sequence is functional in a mammal.
9. A DNA sequence according to claim 8 in which the DNA sequence is expressed in a mammal
10. A DNA sequence according to claim 9 wherein the DNA sequence is expressed in a human.
11. A DNA sequence obtained by modification of a functional natural gene encoding a A-5 fatty acid desaturase according to claim 1 or claim 2. WO 99/33958 PCT/GB98/03895 25
12. A DNA sequence according to claim 11 wherein the modification includes modification by chemical, physical, or biological means without removing a catalytic activity of the enzyme which it encodes.
13. A DNA sequence according to claim 12 wherein the modification improves a catalytic activity of the enzyme which it encodes.
14. A DNA sequence according to claim 12 or 13 wherein the biological modification includes recombinant DNA methods and forced evolution techniques.
15. A DNA sequence according to claim 14 wherein the forced evolution technique is DNA shuffling.
16. A polypeptide encoded by a DNA sequence according to any of claims 3 to 15.
17. A polypeptide according to claim 16 wherein at least a portion of the polypeptide has the sequence shown in SEQ.3 or functional equivalents to that sequence or to portions of that sequence.
18. A polypeptide according to claim 16 wherein at least a portion of the polypeptide has the sequence shown in SEQ.4 or functional equivalents to that sequence or to portions of that sequence.
19. A polypeptide according to any of claims 16 to 18 wherein the polypeptide catalyses the conversion of dihomogamma linolenic acid to arachidonic acid.
20. A polypeptide according to any of claims 16 to 19 wherein the polypeptide has been modified without removing the catalytic activity of the encoded polypeptide.
21. A polypeptide according to claim 20 wherein the polypeptide has been modified in such a way as to introduce a specific level of saturation of a substrate at a specific location within the molecular structure of the substrate.
22. A vector containing a DNA sequence or any portion of a DNA sequence according to any of claims 3 to 15. WO 99/33958 PCT/GB98/03895 26
23. A method of producing polyunsaturated fatty acids comprising contacting a suitable substrate with a A5-fatty acid desaturase according to claim 1 or 2 or a polypeptide according to claim 16 to 21.
24. A method of converting dihomogamma linolenic acid to arachidonic acid wherein said conversion is catalysed by a A5-fatty acid desaturase according to claim 1 or 2 or a polypeptide or modified polypeptide according to any of claims 16 to 21.
25. An organism engineered to produce high levels of a polypeptide according to any of claims 16 to 21.
26. An organism engineered to produce high levels of a product of a reaction catalysed by a A5-fatty acid desaturase according to claim 1 or 2 or by a polypeptide according to any one of claims 16 to 21.
27. An organism which has been engineered to carry out the method of claim 23 or claim 24.
28. An organism according to either of claims 26 and 27 wherein the organism is a microorganism.
29. An organism according to claim 28 wherein a microorganism is selected from algae, bacteria and fungi.
30. An organism according to claim 29 wherein a fungi includes phycomycetes.
31. An organism according to claim 28 wherein said microorganism is a yeast.
32. An organism according to any of claims 25 to 27 wherein the organism is a plant.
33. An organism according to claim 32 wherein the plant is selected from oil seed plants and tobacco. WO 99/33958 PCT/GB98/03895 27
34. An organism according to claim 33 wherein the oil seed plants are selected from oil seed rape, sunflower, cereals including maize, tobacco, legumes including peanut and soybean, safflower, oil palm, coconut and other palms, cotton, sesame, mustard, linseed, castor, borage and evening primrose.
35. A seed or other reproductive material derived from an organism according to claim 33 or claim 34.
36. An organism according to any of claims 25 to 27 wherein the organism is a mammal.
37. An isolated multienzyme pathway wherein the pathway includes a A5 desaturase according to claim 1 or 2 or a polypeptide according to any of claims 16 to 21
38. A compound produced by a conversion of a substrate, wherein said conversion is catalysed by a A5 desaturase according to claim 1 or 2 or by a polypeptide according to any of claims 16 to 21.
39. An intermediate compound produced by the reaction catalysed by a A5 desaturase according to claim 1 or 2 or by a polypeptide according to any of claims 16 to 21.
40. A foodstuff or dietary supplement containing a polyunsaturated fatty acid produced by a method according to claim 23 or 24.
41. A pharmaceutical preparation containing a polyunsaturated fatty acid produced by a method according to claim 23 or 24.
42. Prostaglandins synthesised by a biosynthetic pathway including a catalytic activity of a A5 desaturase according to claim 1 or 2 or by a polypeptide according to any of claims 16 to 21.
43. A method for modulation of prostaglandin synthesis by the control of the levels of expression of a DNA sequence according to any of claims 3 to 15.
44. A probe comprising all or part of a DNA sequence according to any of claims 3 to 15 or an equivalent RNA sequence. WO 99/33958 PCT/GB98/03895 28
45. A diagnostic or search probe comprising all or part of a A5 desaturase according to claim 1 or 2 or of a polypeptide according to any of claims 16 to 21.
46. A method of isolating A5 desaturases using a probe according to claim 44 or 45.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9727256 | 1997-12-23 | ||
| GBGB9727256.1A GB9727256D0 (en) | 1997-12-23 | 1997-12-23 | Desaturase gene |
| GB9814034 | 1998-06-29 | ||
| GBGB9814034.6A GB9814034D0 (en) | 1998-06-29 | 1998-06-29 | Desaturase gene |
| PCT/GB1998/003895 WO1999033958A2 (en) | 1997-12-23 | 1998-12-23 | Desaturase |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003206422A Division AU2003206422A1 (en) | 1997-12-23 | 2003-07-01 | Desaturase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1774899A true AU1774899A (en) | 1999-07-19 |
Family
ID=26312844
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU17748/99A Abandoned AU1774899A (en) | 1997-12-23 | 1998-12-23 | Desaturase |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1042485A2 (en) |
| JP (1) | JP2002508932A (en) |
| KR (1) | KR20010033517A (en) |
| CN (1) | CN1283230A (en) |
| AU (1) | AU1774899A (en) |
| BR (1) | BR9814434A (en) |
| CA (1) | CA2315297A1 (en) |
| EE (1) | EE200000372A (en) |
| HU (1) | HUP0101153A3 (en) |
| PL (1) | PL344868A1 (en) |
| WO (1) | WO1999033958A2 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8791327B2 (en) | 1998-12-07 | 2014-07-29 | Washington State University Research Foundation | Desaturases and methods of using them for synthesis of polyunsaturated fatty acids |
| AU2001263473A1 (en) * | 2000-05-26 | 2001-12-11 | Washington State University Research Foundation | Palmitate desaturase gene |
| ATE510908T1 (en) | 2000-09-28 | 2011-06-15 | Bioriginal Food & Science Corp | FAD5-2, MEMBER OF THE DESATURASE FAMILY AND USES THEREOF |
| GB0107510D0 (en) | 2001-03-26 | 2001-05-16 | Univ Bristol | New elongase gene and a process for the production of -9-polyunsaturated fatty acids |
| GB0229578D0 (en) * | 2002-12-19 | 2003-01-22 | Univ Bristol | Novel method for the production of polyunsaturated fatty acids |
| GB0403452D0 (en) * | 2004-02-17 | 2004-03-24 | Univ York | Desaturase enzymes |
| CN102559364B (en) | 2004-04-22 | 2016-08-17 | 联邦科学技术研究组织 | Use recombinant cell synthesis of long-chain polyunsaturated fatty acids |
| EP1756280B2 (en) | 2004-04-22 | 2024-01-17 | Commonwealth Scientific and Industrial Research Organisation | Synthesis of long-chain polyunsaturated fatty acids by recombinant cells |
| JP4955540B2 (en) | 2004-06-04 | 2012-06-20 | フラクスオーム サイエンセズ エイ／エス | Metabolically modified cells for polyunsaturated fatty acid production |
| EP1780275B1 (en) * | 2004-07-12 | 2010-11-24 | Suntory Holdings Limited | Polypeptide having a delta 5 fatty acid unsaturating activity, polynucleotide coding for the polypeptide and use thereof |
| GB2431158A (en) | 2005-10-13 | 2007-04-18 | Rothamsted Res Ltd | Process for the production of arachidonic and/or eicosapentaenoic acid |
| RU2009111266A (en) | 2006-08-29 | 2010-10-10 | Коммонвелт Сайентифик энд Индастриал Рисерч Организейшн (AU) | FATTY ACID SYNTHESIS |
| CN101376020B (en) * | 2007-08-29 | 2013-05-01 | 益生生技开发股份有限公司 | Application of fungal immunomodulatory protein for inhibiting delta 5-desaturated enzyme |
| BR122021003836B1 (en) | 2008-11-18 | 2022-02-01 | Commonwealth Scientific And Industrial Research Organisation | Isolated and/or exogenous non-naturally occurring polynucleotide, vector and method for producing oil containing unsaturated fatty acids |
| SG11201408362SA (en) | 2012-06-15 | 2015-01-29 | Commw Scient Ind Res Org | Production of long chain polyunsaturated fatty acids in plant cells |
| NZ721036A (en) | 2013-12-18 | 2023-07-28 | Grains Res & Dev Corp | Lipid comprising long chain polyunsaturated fatty acids |
| EP3160482A4 (en) | 2014-06-27 | 2018-02-14 | Commonwealth Scientific and Industrial Research Organisation | Lipid comprising docosapentaenoic acid |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972664A (en) * | 1997-04-11 | 1999-10-26 | Abbott Laboratories | Methods and compositions for synthesis of long chain poly-unsaturated fatty acids |
-
1998
- 1998-12-23 CA CA002315297A patent/CA2315297A1/en not_active Abandoned
- 1998-12-23 WO PCT/GB1998/003895 patent/WO1999033958A2/en not_active Application Discontinuation
- 1998-12-23 EP EP98962620A patent/EP1042485A2/en not_active Withdrawn
- 1998-12-23 AU AU17748/99A patent/AU1774899A/en not_active Abandoned
- 1998-12-23 KR KR1020007007019A patent/KR20010033517A/en not_active Application Discontinuation
- 1998-12-23 JP JP2000526616A patent/JP2002508932A/en active Pending
- 1998-12-23 CN CN98812505A patent/CN1283230A/en active Pending
- 1998-12-23 HU HU0101153A patent/HUP0101153A3/en unknown
- 1998-12-23 PL PL98344868A patent/PL344868A1/en unknown
- 1998-12-23 EE EEP200000372A patent/EE200000372A/en unknown
- 1998-12-23 BR BR9814434-0A patent/BR9814434A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2315297A1 (en) | 1999-07-08 |
| BR9814434A (en) | 2001-10-23 |
| EP1042485A2 (en) | 2000-10-11 |
| WO1999033958A2 (en) | 1999-07-08 |
| CN1283230A (en) | 2001-02-07 |
| EE200000372A (en) | 2001-12-17 |
| HUP0101153A3 (en) | 2006-03-28 |
| JP2002508932A (en) | 2002-03-26 |
| HUP0101153A2 (en) | 2001-08-28 |
| PL344868A1 (en) | 2001-11-19 |
| KR20010033517A (en) | 2001-04-25 |
| WO1999033958A3 (en) | 1999-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Michaelson et al. | Functional identification of a fatty acid Δ5 desaturase gene from Caenorhabditis elegans | |
| EP1911837B1 (en) | FAD5-2 fatty acid desaturase family member and uses thereof | |
| AU1774899A (en) | Desaturase | |
| Wallis et al. | The Δ8-Desaturase ofEuglena gracilis: An Alternate Pathway for Synthesis of 20-Carbon Polyunsaturated Fatty Acids | |
| Michaelson et al. | Isolation of a Δ5-Fatty Acid Desaturase Gene fromMortierella alpina | |
| EP1141252B1 (en) | Human delta 5-desaturase gene and uses thereof | |
| EP1656449B1 (en) | Fatty acid desaturases from primula | |
| EP1790720B1 (en) | Polypeptide having activity of unsaturating omega3-fatty acid, polynucleotide coding for the polypeptide and use thereof | |
| US20020045232A1 (en) | Production of conjugated linoleic and linolenic acids in plants | |
| BRPI0913714A2 (en) | mutant polypeptide that has a5 desaturase activity, isolated nucleic acid molecule, microbial host cell and methods of producing arachidonic acid and eicosapentaenoic acid | |
| KR20070101862A (en) | Recombinant production docosahexaenoic acid(dha) in yeast | |
| JP2013530679A (en) | Up-regulation of the pentose phosphate pathway that enhances the production of the desired non-natural product in transgenic microorganisms | |
| US20030152983A1 (en) | Desaturase | |
| WO1998038314A1 (en) | Δ9-desaturase gene | |
| NO326619B1 (en) | Process for preparing acetylenic compounds using delta-12-acetylenase, DNA sequences encoding the delta-12-acetylenase and organisms transformed with such DNA sequences. | |
| Na-Ranong et al. | Targeted mutagenesis of a fatty acid Δ6-desaturase from Mucor rouxii: role of amino acid residues adjacent to histidine-rich motif II | |
| Kim et al. | Functional characterization of polyunsaturated fatty acid delta 6-desaturase and elongase genes from the black seabream (Acanthopagrus schlegelii) | |
| RU2266330C2 (en) | BIOLOGICALLY ACTIVE ANIMAL FATTY ACID Δ5-DESATURASE, DNA SEQUENCE ENCODING THE SAME, CLONING END EXPRESSING VECTORS CONTAINING SAID SEQUENCE, METHOD FOR PRODUCTION OF POLYUNSATURATED FATTY ACIDS, METHOD FOR CONVERTING OF DIHOMO-γ-LINOLENIC ACID TO ARACHIDONIC ACID, PROBE (VARIANTS), AND METHOD FOR DETECTION OF Δ5-DESATURASE USING THE SAME | |
| MXPA00006158A (en) | Desaturase | |
| CN101724637B (en) | Nucleotide sequence of delta 9 extending enzyme of chromulina, such as ball and the like, and application thereof | |
| AU2013202498B2 (en) | Isolation and characterization of a novel Pythium omega 3 desaturase with specificity to all omega 6 fatty acids longer than 18 carbon chains | |
| AU720765C (en) | Novel plant enzyme and use thereof | |
| JPH09121873A (en) | Cytochrome b5 gene | |
| Tan | Cloning and functional analysis of the genes from entomopathogenic fungi involved in the biosynthesis of eicosatetraenoic acid (ETA) | |
| JPH10113181A (en) | Cytochrome b5 reductase gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |